REALQUALITY RQ-Multi HPV Detection

Description

The REALQUALITY RQ-Multi HPV Detection kit is an IVD for detection of the DNA of 14 high-risk, 6 possibly high-risk and 8 low-risk genotypes of the Human Papillomavirus (HPV) and genotyping of HPV 16 and HPV 18 by Real-Time PCR.

Product Characteristics

• The device is validated on DNA extracted from various sample types;
• The assay requires only 5 µL of DNA extracted;
• The kit allows the detection of 14 high-risk genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), 6 possibly high-risk genotypes (HPV 26, 53, 67, 70, 73, 82) and 8 low-risk genotypes (HPV 6, 11, 40, 42, 43, 44, 55, 83) of Human Papillomavirus in two reactions;
• The kit is able to specifically identify the HPV 16 and HPV 18 genotypes;
• The assay shares the same thermal profile of the REALQUALITY Infectious diseases kits and the REALQUALITY STI kits;
• Validated on main Real-Time PCR instruments;
• The assay includes dUTP/UNG system for preventing carry-over contamination and a fluorescence normalizer;
• The automatic format of the assay can be used on GENEQUALITY® platform
• Easy interpretation of results with AB Genius Report software.

Kit content

The kit includes:

• Ready-to-use reagents for Real-Time PCR
• Internal control
• Positive control

Further Information

Human Papillomavirus (HPV) infection is the most common and widespread of sexually transmitted diseases. The different types of HPV are generally divided into low-risk and high-risk cancer risk genotypes. The latter (in particular HPV 16 and 18) are recognized as the necessary cause of cervical cancer and, in general, among the most important carcinogenic viruses for the human species. The transforming role, in fact, does not end in genesis of the cervical carcinoma, but it is strongly correlated to other neoplasms of the female and male genital sphere (vulva, vagina, anus, penis) and extragenital neoplasms (oral cavity, pharynx, larynx). The carcinogenic potentials can be ascribed to two viral oncoproteins (E6 and E7) which, after the integration of the viral genome into the host genome, cause an uncontrolled proliferative stimulus. This leads to a decrease capability in controlling the cellular surveillance mechanisms, with consequent accumulation of genetic abnormalities, increased genomic instability and the appearance of aneuploidy.
During the process of viral integration, part of the HPV DNA may be lost. However, this process never involves the E6 and E7 genes, so using a screening system targeting those genes exclude the possibility of false negative results due to viral integration events.

Ordering Information